As of July 2026, not a single randomized controlled trial has been published showing that any over-the-counter "GLP-1 patch" produces meaningful weight loss in humans
The authors emphasize that the potential risk of NAION with GLP-1 RA therapy warrants further investigation, particularly given the growing use of these agents and the significant impact of NAION on vision
Travel delays, temperature issues, or unexpected situations can happen
As Kaiser Permanente prepares to revise its coverage criteria in 2025, many individuals are left uncertain about their access to essential treatments for obesity-related conditions
Contact your healthcare provider if you experience: Severe or persistent gastrointestinal symptoms Whilst nausea, vomiting, and diarrhoea are common when starting Saxenda, symptoms that are severe, worsening, or not improving with dose stabilisation require assessment